Circulating Tumor DNA Using Tagged Targeted Deep Sequencing to Assess Minimal Residual Disease in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
07
2019
revised:
31
10
2019
accepted:
18
11
2019
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
8
5
2020
Statut:
epublish
Résumé
In breast cancer patients undergoing neoadjuvant chemotherapy before surgery, there is an unmet need for noninvasive predictive biomarkers of response. The analysis of circulating tumor DNA (ctDNA) in particular has been the object of several reports, but few of them have studied the applicability of tagged targeted deep sequencing (tTDS) to clinical practice and its performance compared with droplet digital PCR (ddPCR). Here, we present the first results from an ongoing study involving a prospectively accrued, monocentric cohort of patients affected by invasive breast cancer, undergoing neoadjuvant chemotherapy followed by surgery with curative intent as per clinical practice. A pretreatment tumor biopsy and plasma samples were collected before and during treatment, after surgery, and every six months henceforth or until relapse, whichever came first. Pretreatment biopsies were sequenced with a 409-gene massive parallel sequencing (MPS) panel, allowing the identification of target mutations and their research in plasma by tTDS and ddPCR as a complementary approach. Using tTDS, we demonstrated the presence of at least one deleterious mutation in all the relapsed cases we studied (
Identifiants
pubmed: 32377196
doi: 10.1155/2020/8132507
pmc: PMC7196957
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8132507Informations de copyright
Copyright © 2020 Gabriella Cirmena et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Références
Oncotarget. 2018 Apr 6;9(26):18529-18539
pubmed: 29719623
Breast Cancer Res Treat. 2014 Jul;146(1):163-74
pubmed: 24838941
Sci Transl Med. 2015 Aug 26;7(302):302ra133
pubmed: 26311728
Br J Cancer. 2005 May 23;92(10):1948-52
pubmed: 15841077
Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):E5503-12
pubmed: 26392541
Cell. 2016 Jan 14;164(1-2):57-68
pubmed: 26771485
Oncotarget. 2016 Oct 25;7(43):71013-71035
pubmed: 27589834
Exp Ther Med. 2015 Apr;9(4):1383-1388
pubmed: 25780439
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18761-8
pubmed: 24191000
J Clin Oncol. 2006 Sep 10;24(26):4270-6
pubmed: 16963729
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Clin Chem. 2013 Jan;59(1):211-24
pubmed: 23065472
EMBO Mol Med. 2015 Aug;7(8):1034-47
pubmed: 25987569
J Natl Cancer Inst. 2014 May 15;106(5):
pubmed: 24832787
J Transl Med. 2019 Apr 29;17(1):137
pubmed: 31036005
Genome Res. 2019 Mar;29(3):418-427
pubmed: 30808726
Nat Commun. 2017 Apr 20;8:14944
pubmed: 28429735
Mol Med. 2019 Apr 27;25(1):15
pubmed: 31029076
Breast Cancer Res. 2013;15(5):211
pubmed: 24090167
Nat Genet. 2016 Oct;48(10):1273-8
pubmed: 27571261
Biomed Res Int. 2018 May 8;2018:7392419
pubmed: 29854785
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Cancer Treat Rev. 2013 Nov;39(7):691-700
pubmed: 23683721